DEVELOPMENT AND VALIDATION OF AN RP-HPLC METHOD FOR SIMULTANEOUS ESTIMATION OF COBICISTAT AND ATAZANAVIR IN BULK AND PHARMACEUTICAL DOSAGE FORM

Аннотация

This research paper focuses on the development and validation of an RP-HPLC (Reverse-Phase High-Performance Liquid Chromatography) method for the simultaneous estimation of cobicistat and atazanavir in bulk and pharmaceutical dosage form. Cobicistat and atazanavir are important antiretroviral drugs used in the treatment of HIV infection. The development of a reliable and accurate analytical method for their simultaneous determination is essential for quality control and pharmacokinetic studies. The RP-HPLC method was optimized by considering factors such as column selection, mobile phase composition, flow rate, and detection wavelength. Validation parameters including linearity, precision, accuracy, specificity, robustness, and system suitability were evaluated according to international guidelines. The developed method demonstrated good linearity, sensitivity, and selectivity for the simultaneous estimation of cobicistat and atazanavir in both bulk and pharmaceutical dosage form. The findings of this study provide a robust and reliable analytical method that can be utilized for routine analysis and quality control of cobicistat and atazanavir formulations. KEYWORDS RP-HPLC, Cobicistat, Atazanavir, Simultaneous estimation, Validation, Bulk, Pharmaceutical dosage form, Antiretroviral drugs, HIV, Quality control.